Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial

Ítems similars

• Dose REduction strategy of subcutaneous TNF inhibitors in rheumatoid arthritis: design of a pragmatic randomised non inferiority trial, the DRESS study
  per: den Broeder, Alfons A, et al.
  Publicat: (2013)
• What causes a small increase in radiographic progression in rheumatoid arthritis patients tapering TNF inhibitors?
  per: Bouman, Chantal A M, et al.
  Publicat: (2017)
• Down‐titration and discontinuation strategies of tumour necrosis factor–blocking agents for rheumatoid arthritis in patients with low disease activity
  per: Verhoef, Lise M, et al.
  Publicat: (2019)
• Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study
  per: van der Maas, Aatke, et al.
  Publicat: (2012)
• Dose reduction and withdrawal strategy for TNF-inhibitors in psoriatic arthritis and axial spondyloarthritis: design of a pragmatic open-label, randomised, non-inferiority trial
  per: Michielsens, Celia A. J., et al.
  Publicat: (2020)